Small font size A Larger text size A Largest text size A

Halozyme Therapeutics Prices $1.3 Billion Private Debt Offering

BY MT Newswires | CORPORATE | 11/07/25 04:10 AM EST

04:10 AM EST, 11/07/2025 (MT Newswires) -- Halozyme Therapeutics (HALO) said late Thursday it priced a private offering of $650 million of 0% convertible senior notes due 2031 and $650 million of 0.875% convertible senior notes due 2032.

Initial purchasers have a 13-day overallotment option to purchase up to $100 million of additional notes of each series.

Net proceeds, estimated to be $1.27 billion to $1.47 billion, will be used to fund certain capped call transactions, among other things, the company said.

Halozyme expects the offering to close Wednesday.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

More Fixed Income News

Wall St Week Ahead-Fed's internal split puts spotlight on Powell's rate guidance, dissents BY Reuters |ECONOMIC 09:00 AM EST
Fed's internal split puts spotlight on Powell's rate guidance, dissents BY Reuters |ECONOMIC 08:59 AM EST
MIDEAST STOCKS-Most Gulf markets gain on US rate cut hopes BY Reuters |ECONOMIC 08:01 AM EST
France's Macron threatens China with tariffs over trade surplus - Les Echos BY Reuters |ECONOMIC 07:57 AM EST

All Fixed Income News

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article